The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

Basit Öğe Kaydı
dc.authoridAnkaralı, Handan Camdeviren/0000-0002-3613-0523
dc.authoridoltulu, pembe/0000-0003-3273-671X
dc.authorwosidAnkaralı, Handan Camdeviren/P-1058-2016
dc.contributor.authorEski, Mehmet Tahir
dc.contributor.authorTeberik, Kuddusi
dc.contributor.authorOltulu, Pembe
dc.contributor.authorAnkaralı, Handan
dc.contributor.authorKaya, Murat
dc.contributor.authorAlpay, Merve
dc.date.accessioned2023-07-26T11:51:07Z
dc.date.available2023-07-26T11:51:07Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractPurpose To investigate the effects of subconjunctival bevacizumab, ranibizumab, and aflibercept in an experimental corneal neovascularization model. Materials and methods The eyes of 24 rats were chemically cauterized and randomly divided into four groups: bevacizumab group (0.05 mL/1.25 mg bevacizumab), ranibizumab group (0.05 mL/0.5 mg ranibizumab), aflibercept group (0.05 mL/1.25 mg aflibercept), and control group (0.05 mL saline solution). Plasma vascular endothelial growth factor (VEGF) levels were among the major measurement outcomes to assess corneal neovascularization. The collected plasmas were analyzed using the SIGMA RAB0511 Rat VEGF Elisa kit. The PCR technique and VEGF amplification procedures were used for molecular analysis. Each cornea was removed and histologically examined on day 21. Corneal images were evaluated by image analyzer software. Results In the post-injection period, the number of major corneal arteries decreased significantly in the injection groups when compared to the control group (p = 0.037), but no statistically significant differences were noted among the injection groups (p > 0.05). The aflibercept group had the lowest area of neovascularization. Immunohistochemical staining revealed substantially lower VEGF percentages in neovascularized arteries of the injection groups than the control group (p = 0.015). In TUNEL staining, the mean TUNEL value (number/1hpf) was substantially greater in the control group than in the injection groups, but the mean TUNEL values were similar between the injection groups (p = 0.019, p > 0.05, respectively). No statistically significant differences were observed between the groups in terms of corneal surface area with increased cellularity, edema, and inflammation (p = 0.263). The mean plasma VEGF concentration in the control group was statistically greater than those in the injection groups (p = 0.001). Conclusion Subconjunctival bevacizumab, ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting corneal neovascularization without causing epitheliopathy in an experimental rat model compared to the controls. However, no significant results were noted between these three anti-VEGF molecules.en_US
dc.description.sponsorshipDuzce University Research Fund Project [2016.04.02.473]en_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project is supported by Duzce University Research Fund Project [Grant Number: 2016.04.02.473].en_US
dc.identifier.doi10.1177/09603271221084674
dc.identifier.issn0960-3271
dc.identifier.issn1477-0903
dc.identifier.pmid35465742en_US
dc.identifier.scopus2-s2.0-85128800857en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1177/09603271221084674
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12498
dc.identifier.volume41en_US
dc.identifier.wosWOS:000787650000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorTeberik, Kuddusi
dc.institutionauthorKaya, Murat
dc.institutionauthorAlpay, Merve
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofHuman & Experimental Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectCorneal Neovascularization; Vascular Endothelial Growth Factor; Subconjunctival Injection; Tunel Staining; Immunohistochemical Examinationen_US
dc.subjectGrowth-Factor Vegf; Topical Bevacizumab; Inhibition; Injection; Angiogenesis; Prevention; Efficacy; Lucentis; Therapy; Eyeen_US
dc.titleThe effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularizationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12498.pdf
Boyut:
1.32 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu